SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media & Technology Group Corp. (DJT) is trending following news of its merger with nuclear fusion company TAE Technologies, sparking fervent discussion. Supporters view this unexpected pivot into the energy sector as a visionary move with potential for significant growth, especially in powering AI infrastructure. Conversely, many skeptics express concerns about dilution and the highly speculative nature of commercial fusion, questioning the long-term viability and profitability of this ambitious venture.

Rocket Lab Corp. engages in the development of rocket launch and control systems for the space and defense industries. It operates through the Launch Services and Space Systems segments. The Launch Services segment provides launch services to customers on a dedicated mission or ride share basis. The Space Systems segment consists of spacecraft engineering and design services, spacecraft components, spacecraft manufacturing, and on-orbit mission operations. The company is headquartered in Long Beach, CA.

Rocket Lab Corp.

Rocket Lab USA Inc

Rocket Lab is experiencing a significant surge following its largest contract win to date, securing an $816 million prime award from the U.S. Space Force to develop 18 missile-defense satellites. This achievement is validating the company's transition into an end-to-end space and defense manufacturer, driving strong positive sentiment among investors who foresee continued growth and a potential re-rating of the stock within the evolving space sector.

Flora Growth Corp. engages in the production of organic cannabis and pharmaceutical-grade medical products. It operates through the following segments: House of Brands and Commercial and Wholesale. The House of Brands segment includes multiple categories including food and beverage, nutraceuticals, cannabis accessories and technology, personal care and wellness. The Commercial and Wholesale segment includes distribution of pharmaceutical products to international markets. The company was founded on March 13, 2019 and is headquartered in Fort Lauderdale, FL.

Flora Growth Corp

Flora Growth Corp. is trending due to its strategic pivot and rebranding as ZeroStack, now focused on a significant crypto treasury strategy involving 0G tokens for decentralized AI infrastructure. The community is actively discussing the perceived massive undervaluation, highlighting its substantial crypto holdings against a low market capitalization and strong short-squeeze potential. This hybrid cannabis and AI-blockchain play has generated significant buzz, with many anticipating a substantial surge.

Newegg Commerce, Inc. is an e-commerce company. It offers direct sales and an online marketplace platform for IT computer components, consumer electronics, entertainment, smart home and gaming products. The firm also provides third-party logistics services globally. The company was founded on July 22, 2003 and is headquartered in City of Industry, CA.

Newegg Commerce Inc

Newegg Commerce is experiencing intense investor interest driven by recent insider share acquisitions, with a major holder significantly increasing their stake, leading to widespread community anticipation of a substantial short squeeze. Conversations are centered on an increasingly tight share float and perceived manipulation by short sellers, with many believing upcoming earnings and strategic partnerships could force significant covering.

BigBear.ai Holdings, Inc. engages in data-driven decision dominance and advanced analytics that provide its customers with a competitive advantage in a world driven by data that is growing in terms of volume, variety, and velocity. The firm operationalizes artificial intelligence and machine learning at scale through its end-to-end data analytics platform. It deploys its observe, orient and dominate products to customers throughout the defense, intelligence, and commercial markets. The company was founded in 2020 and is headquartered in McLean, VA.

BigBear.ai Holdings Inc

BigBear.ai is a major talking point due to high anticipation surrounding a potential significant contract with the TSA for AI-enabled border security, following successful pilot programs. This speculation, combined with a new strategic partnership with C Speed aimed at enhancing defense missions, is fueling community optimism about the company's long-term growth in the AI defense sector. Meanwhile, a pending shareholder vote to increase authorized shares is also generating considerable discussion, with investors weighing the need for capital against potential dilution.

A fun meme coin with no utility beyond spreading Christmas cheer. X is exploding with people changing their profile pictures to include a Santa Hat, we are taking advantage of the hype and launched the perfect token for it. Beyond that, there is no function. Just spreading joy this season. Elon Musk himself changed his profile picture. The coin is run by one of the biggest influencers on X No utility, run purely on hype and memes

SANTA HAT

SANTAHAT CRYPTO is a trending topic across the crypto community, frequently mentioned alongside other prominent digital assets and meme coins. Community members are actively discussing its prospects with optimistic sentiment, often expressing 'WAGMI' aspirations. This surge in interest appears driven by speculative fervor and a thematic appeal resonating with traders.

Cytokinetics, Inc. is a biopharmaceutical company, which is focused on discovering, developing, and commercializing muscle activators and muscle inhibitors as potential treatments for people with debilitating diseases in which muscle performance is compromised and/or declining. The firm is developing small molecule drug candidates specifically engineered to impact muscle function and contractility. Its clinical-stage drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator, CK-136, a novel cardiac troponin activator, reldesemtiv, a novel fast skeletal muscle troponin activator, aficamten, a novel cardiac myosin inhibitor, and CK-3772271, a novel cardiac myosin inhibitor. The company was founded by Ronald D. Vale, Lawrence S. B. Goldstein, James H. Sabry, and James A. Spudich in 1997 and is headquartered in South San Francisco, CA.

Cytokinetics Inc

Cytokinetics is actively trending following its FDA approval for MYQORZO (aficamten) for obstructive hypertrophic cardiomyopathy and strong MAPLE-HCM trial data showing superiority over standard-of-care. The community is debating the stock's price action post-approval, its differentiation from competitors like Camzyos, and persistent buyout speculation, often coupled with strong opinions on management's strategy and future sales potential.

Whirlpool Corp. engages in the manufacturing and marketing of home appliances. Its products include home laundry appliances, refrigerators and freezers, cooking appliances, home dishwashers, and room air-conditioning equipment, mixers, and portable household appliances. The firm's brands include Whirlpool, KitchenAid, Maytag, Consul, Brastemp, Amana, Bauknecht, JennAir, and Indesit. It operates through the following segments: North America, Europe, Middle East and Africa (EMEA), Latin America, and Asia. The company was founded by Emory Upton, Fred Upton, and Louis C. Upton on November 11, 1911 and is headquartered in Benton Harbor, MI.

Whirlpool Corp.

Whirlpool is trending due to recent financial results and intensifying conversations around trade tariffs, with a significant institutional investor increasing their stake. The community is actively debating the company's position as a potential tariff winner given its domestic manufacturing, while also watching for a rumored asset sale amidst persistent concerns about broader consumer demand and housing market conditions.

Redwire Corp. manufactures and supplies space equipment. It offers critical space solutions and reliability components for the next generation space economy with IP for solar power generation and in-space 3D printing and manufacturing. It assists its customers in solving challenges of future space missions. The company was founded in 2020 and is headquartered in Jacksonville, FL.

Redwire Corporation

Redwire Corp

Redwire is garnering significant investor attention following an eight-figure contract win for spacecraft docking systems, alongside recent DARPA awards and discussions by its CTO on advanced solar arrays for space-based data centers. The stock is experiencing record trading volume, with the community actively speculating on its undervalued position within the expanding space and defense sectors.

Sperax is redefining financial autonomy through programmable agents that manage capital, optimize yield, and protect against risk, all transparently on-chain. Founded in 2019, Sperax is backed by leading investors including Jump Trading, Polychain Capital, Amber Group. Sperax offers a new standard in automated, user-driven finance.  The SperaxOS ecosystem is powered by USDs and SPA on Arbitrum, BNB Chain, and other EVM networks. Anchored by two native assets: USDs, a gas-free, auto-yield stablecoin backed by on-chain collateral, and SPA, the governance and value-capture token. Sperax builds open-source tools that turn idle capital into self-optimizing portfolios.  SperaxOS is a cross-chain financial operating system where AI-driven smart agents automate everything from yield farming to payroll, and Demeter, a no-code platform for launching liquidity farms. USDs automatically rebases yield to holders, while SPA lets users register agents, earn protocol fees, and vote on upgrades. Battle-tested through multiple market cycles: Sperax offers individuals, DAOs, and fintechs a borderless toolkit for passive income, risk-managed investing, and fully automated treasury operations, all governed on-chain by its community.

Sperax

Sperax (SPA) is capturing significant attention as the crypto community anticipates the launch of its SperaxOS, an AI-powered yield system, amidst discussions around the incoming "GENIUS Act" and its potential positive impact on compliant stablecoins like USDs. Traders are actively debating whether recent high trading volume and new exchange listings signal an imminent breakout, with many believing the project's fundamentals and regulatory alignment position it for a substantial rally after a period of suppressed price movement.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

BioMarin Pharmaceutical (NASDAQ:BMRN) Shares Gap Up - Here's Why

BioMarin Pharmaceutical (NASDAQ:BMRN) Shares Gap Up - Here's What Happened...

Stock Traders Buy High Volume of Call Options on BioMarin Pharmaceutical (NASDAQ:BMRN)

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Get Free Report) was the recipient of unusually large options trading on Friday. Stock investors acquired 3,079 call options on the company. This is an...

<ul class="summary-bullets"><li>The deal values Amicus at $14.50 per share, representing a 33% premium to its $10.90 closing price on Thursday.</li><li>Amicus settled its patent dispute with Indian drugmakers Aurobindo Pharma and Lupin over proposed generic versions of Galafold.</li><li>BioMarin plans to fund the acquisition with a mix of existing cash and about $3.7 billion in new debt</li></ul>Amicus Therapeutics (FOLD) shares jumped more than 30% in on Friday, to their highest level since January 2024, after BioMarin Pharmaceutical (BMRN) agreed to acquire the company in a $4.8 billion all-cash deal.The deal values Amicus at $14.50 per share, representing a 33% premium to its $10.90 closing price on Thursday. The transaction is expected to close in the second quarter of fiscal 2026. Biomarin shares gained 6.6%.Both <a href="https://stocktwits.com/symbol/FOLD">FOLD</a> and <a href="https://stocktwits.com/symbol/BMRN">BMRN</a> were among the top trending tickers on Stocktwits.<h2 class="st-heading-2">Portfolio Expansion And Revenue Pipeline</h2>The acquisition will expand BioMarin’s portfolio, adding two new treatments to its existing medicines for rare inherited metabolic disorders.Galafold for Fabry disease and Pombiliti + Opfolda for Pompe disease generated $599 million in combined net revenues over the past four quarters. U.S. exclusivity for Galafold is projected through January 2037 following recent patent settlements.The deal is expected to boost revenue as soon as it closes and add to earnings within the first year. BioMarin expects the acquisition to become meaningfully more accretive from 2027.The company plans to fund the acquisition with a mix of existing cash and about $3.7 billion in new debt, with Morgan Stanley providing a bridge financing commitment.<h2 class="st-heading-2">IP Dispute Update</h2>Separately, Amicus settled its patent dispute with Indian drugmakers Aurobindo Pharma and Lupin over proposed generic versions of Galafold. Under the agreements, the companies will be allowed to launch generics in the U.S. starting January 30, 2037, subject to FDA approval.As part of the settlement, all ongoing Hatch-Waxman litigation between the parties will be terminated, and U.S. antitrust authorities will review the agreements.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment for Biomarin on Stocktwits turned ‘extremely bullish’ from ‘bullish’ a day earlier, amid ‘high' message volumes.&nbsp;<figure class="image"><img style="aspect-ratio:904/100;" src="https://news.stocktwits-cdn.com/BMRN_png_a8236939f5.webp" alt="BMRN.png" width="904" height="100"><figcaption>BMRN's Sentiment Meter And Message Volumes at Premarket on Dec. 18, 2025 | Source: Stocktwits</figcaption></figure>One user highlighted the visibility of BMRN’s FY2027 revenue target.<stembedurl>https://stocktwits.com/DairyQueen505/message/639674012</stembedurl>Retail sentiment for Amicus on the platform remained in the ‘extremely bullish’ zone over the past 24 hours, amid ‘extremely high message volumes.<figure class="image"><img style="aspect-ratio:922/99;" src="https://news.stocktwits-cdn.com/fold_png_a408903f4b.webp" alt="fold.png" width="922" height="99"><figcaption>FOLD's Sentiment Meter and Message Volumes at Premarket on Dec. 18, 2025 | Source: Stocktwits</figcaption></figure>Year-to-date, FOLD stock has gained 15% while BMRN has declined over 20%.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/this-new-product-launch-is-lifting-amesite-shares-premarket/cLeiw0iREs7">This New Product Launch Is Lifting Amesite Shares Premarket — Here’s What Investors Are Watching</a> For updates and corrections, email newsroom[at]stocktwits[dot]com.

Amicus Stock Surges To Near 2-Year Highs On BioMarin's $4.8B Buyout Deal

The acquisition will add two new treatments to BioMarin’s existing medicines for rare inherited metabolic disorders.

Equity

BioMarin To Acquire Amicus Therapeutics For Around $4.8 Bln

(RTTNews) - BioMarin Pharmaceutical Inc. (BMRN), a pharmaceutical company, Friday announced that it has entered into a definitive agreement to acquire Amicus Therapeutics (FOLD), a biotech company...

BioMarin to Acquire Amicus Therapeutics for $4.8 Billion, Expanding Position as a Leader in Rare Diseases, Accelerating Revenue Growth and Strengthening Financial Outlook

BioMarin to Acquire Amicus Therapeutics for $4.8 Billion, Expanding Position as a Leader in Rare Diseases, Accelerating Revenue Growth and Strengthening Financial Outlook BioMarin to Acquire Amicus...

Do Options Traders Know Something About BMRN Stock We Don't?

Investors need to pay close attention to BioMarin Pharmaceutical stock based on the movements in the options market lately.

Hudson Bay Capital Management LP Sells 60,425 Shares of BioMarin Pharmaceutical Inc. $BMRN

Hudson Bay Capital Management LP decreased its holdings in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) by 10.3% in the second quarter, according to its most recent Form 13F filing with...

BioMarin Pharmaceutical Inc. $BMRN Holdings Lowered by Hudson Bay Capital Management LP

Hudson Bay Capital Management LP cut its stake in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) by 10.3% in the 2nd quarter, according to its most recent Form 13F filing with the...

Boone Capital Management LLC Has $24.60 Million Position in BioMarin Pharmaceutical Inc. $BMRN

Boone Capital Management LLC lifted its position in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) by 36.7% in the 2nd quarter, according to the company in its most recent Form...

Bellevue Group AG Lowers Stake in BioMarin Pharmaceutical Inc. $BMRN

Bellevue Group AG cut its stake in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) by 58.9% during the second quarter, according to its most recent 13F filing with the Securities and...

BioMarin Pharmaceutical, Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its pipeline products include Valoctocogene roxaparvovec, Vosoritide, and BMN 307. The company was founded by John C. Klock, Christopher M. Starr and Grant W. Denison on March 21, 1997, and is headquartered in San Rafael, CA.

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '25	$0.81	--	--	N/A
Q3 '25	$0.81	-$0.16	-119.77%	MISSED
Q2 '25	$0.82	$1.23	50.27%	BEAT
Q1 '25	$0.68	$0.95	39.21%	BEAT
Q4 '24	$0.53	$0.64	19.84%	BEAT

BMRN
Biomarin Pharmaceutical Inc. - Registered Shares

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q4 '25

Historical Earnings

Latest BMRN News

BMRNBiomarin Pharmaceutical Inc. - Registered Shares